ENDRA Life Sciences Inc. (NDRA) Insider Trading Disclosures
ENDRA Life Sciences Inc. (NDRA) is a publicly traded company on the Nasdaq, categorized under SIC 3845 (Electromedical & Electrotherapeutic Apparatus). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: NDRA
CIK: 1681682
Exchange: Nasdaq
SIC 3845: Electromedical & Electrotherapeutic Apparatus
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
RBSM LLP
Auditor SinceSince 12/31/2016 12:00:00 AM
Lead Engagement PartnerFRANK PARRISH
Audit LocationHOUSTON, Texas, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 3 | 2026-10-08 | 2026-10-01 | FORM 3 | 0001477932-26-006129 | View SEC Doc Filr Page |
| SCHEDULE 13D | 2026-10-08 | — | SCHEDULE 13D Filing | 0001477932-26-006128 | View SEC Doc Filr Page |
| S-4 | 2026-10-02 | — | S-4 | 0001193125-26-410883 | View SEC Doc Filr Page |
| 425 | 2026-10-01 | — | CURRENT REPORT | 0001213900-26-105909 | View SEC Doc Filr Page |
| 8-K | 2026-10-01 | 2026-10-01 | CURRENT REPORT | 0001213900-26-105899 | View SEC Doc Filr Page |
| 425 | 2026-09-25 | — | FORM 425 | 0001213900-26-103599 | View SEC Doc Filr Page |
| 425 | 2026-09-14 | — | FORM 425 | 0001213900-26-099784 | View SEC Doc Filr Page |
| 425 | 2026-09-09 | — | 425 | 0001477932-26-005473 | View SEC Doc Filr Page |
| 425 | 2026-09-09 | — | FORM 425 | 0001477932-26-005472 | View SEC Doc Filr Page |
| 425 | 2026-08-21 | — | FORM 425 | 0001477932-26-005199 | View SEC Doc Filr Page |
| 425 | 2026-08-20 | — | 425 | 0001193125-26-358082 | View SEC Doc Filr Page |
| 425 | 2026-08-17 | — | CURRENT REPORT | 0001213900-26-090755 | View SEC Doc Filr Page |
| 8-K | 2026-08-17 | 2026-08-17 | CURRENT REPORT | 0001213900-26-090747 | View SEC Doc Filr Page |
| 10-Q | 2026-08-14 | 2026-06-30 | QUARTERLY REPORT | 0001213900-26-090027 | View SEC Doc Filr Page |
| 425 | 2026-08-06 | — | 425 | 0001193125-26-336866 | View SEC Doc Filr Page |
| 425 | 2026-08-05 | — | 425 | 0001193125-26-335463 | View SEC Doc Filr Page |
| 425 | 2026-08-04 | — | 425 | 0001193125-26-333141 | View SEC Doc Filr Page |
| 425 | 2026-07-22 | — | 425 | 0001477932-26-004439 | View SEC Doc Filr Page |
| 425 | 2026-07-22 | — | 425 | 0001477932-26-004434 | View SEC Doc Filr Page |
| 425 | 2026-07-17 | — | FORM 425 | 0001477932-26-004369 | View SEC Doc Filr Page |
| 425 | 2026-07-17 | — | FORM 425 | 0001213900-26-078913 | View SEC Doc Filr Page |
| 8-K | 2026-07-09 | 2026-07-08 | CURRENT REPORT | 0001213900-26-076526 | View SEC Doc Filr Page |
| SCHEDULE 13D/A | 2026-06-29 | — | SCHEDULE 13D/A Filing | 0001213900-26-073318 | View SEC Doc Filr Page |
| 425 | 2026-06-26 | — | CURRENT REPORT | 0001213900-26-072270 | View SEC Doc Filr Page |
| 8-K | 2026-06-26 | 2026-06-25 | CURRENT REPORT | 0001213900-26-072268 | View SEC Doc Filr Page |